Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Hydroxyurea
Drug ID BADD_D01110
Description An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indications and Usage For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Marketing Status Prescription; Discontinued
ATC Code L01XX05
DrugBank ID DB01005
KEGG ID D00341
MeSH ID D006918
PubChem ID 3657
TTD Drug ID D07CWD
NDC Product Code 70518-0916; 0904-6939; 51927-0072; 49452-3650; 0003-6337; 60429-265; 55154-7143; 0003-0830; 10135-702; 71770-120; 49884-724; 55512-0003; 68084-284; 51552-0851; 17337-0022; 0003-6336; 35369-0006; 0555-0882; 0003-6335; 42291-321; 51927-2655; 71052-323; 69315-164; 17337-0023; 71770-105
Synonyms Hydroxyurea | Hydroxycarbamid | Oncocarbide | Hydrea
Chemical Information
Molecular Formula CH4N2O2
CAS Registry Number 127-07-1
SMILES C(=O)(N)NO
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Chronic myeloid leukaemiaTyrosine-protein kinase ABL1P00519T6350511841409; 11273186; 9516377; 15510207
HepatomegalyTyrosine-protein kinase ABL1P00519T6350511841409; 11273186; 9516377; 15510207
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Portal hypertension24.08.06.001; 09.01.06.0060.000533%
Portal vein thrombosis24.01.03.003; 09.01.06.0070.000533%
Premature baby18.04.02.0010.000799%Not Available
Premature delivery18.07.01.0060.000799%
Prostatic disorder21.04.01.0010.000533%Not Available
Prothrombin time ratio decreased13.01.02.0400.000533%Not Available
Pruritus23.03.12.001--
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary fibrosis22.01.02.0060.000139%
Pulmonary hypertension24.08.03.002; 22.06.01.0010.000139%
Pulmonary oedema22.01.03.003; 02.05.02.0030.000533%
Pyelonephritis20.01.09.001; 11.01.14.0020.000799%Not Available
Pyoderma gangrenosum10.04.02.009; 23.07.03.001; 16.32.03.0050.000533%Not Available
Pyrexia08.05.02.0030.011189%
Radiation injury12.05.02.003--Not Available
Rash23.03.13.001--Not Available
Rash erythematous23.03.06.0030.000799%Not Available
Rash generalised23.03.13.0020.000533%Not Available
Rash maculo-papular23.03.13.004--
Rash papular23.03.13.017--Not Available
Red blood cell count decreased13.01.05.0070.001332%Not Available
Renal disorder20.01.02.0020.001066%Not Available
Renal failure20.01.03.0050.000486%Not Available
Renal tubular disorder20.05.03.004--Not Available
Respiratory disorder22.02.07.0020.000799%Not Available
Respiratory distress22.02.01.0120.000533%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000417%
Reticulocytopenia01.07.02.004--Not Available
Scleroderma23.03.02.005; 15.06.01.002; 10.04.07.0010.000533%Not Available
Second primary malignancy16.16.01.0140.001112%
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 14 Pages